Syros Pharmaceuticals (SYRS) Tops Q3 EPS by 67c

Syros Pharmaceuticals (NASDAQ: SYRS) reported Q3 EPS of ($3.21), $0.67 better than the analyst estimate of ($3.88). Revenue for the quarter came in at $3.9 million versus the consensus estimate of $5.18 million.

For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.

You May Also Be Interested In

• Solstice acquiring Element Solutions in $14.5B cash and stock deal
• Best Idea Q3 2026: Ryanair (RYAAY) PT Raised to $79 at Bernstein SocGen
• Vontier completes sale of Teletrac Navman for $220 million